

Development Center for Biotechnology (DCB)

Institute of Pharmaceutics

Institute of Biologics

Institute for Drug Evaluation Platform

Laboratory of Translational Medicine

Lead
Discovery

Validation
Optimization

Preclinical
Pharm, Tox

IND

Phase I, II, III
Clinical Trials

NDA

Market

RD

Drug Commercialization Center

Division of Business Development
and Technology Transfer

Nankang Biotech Incubation Center (NBIC)

BD

BPIPO

Division of Industrial Information

Drug Commercialization Center (DCC)

www.biip-dcc.org



Model Executed By DCC/DCB



Focus Fields:

- Cancer
- Infective Diseases
- Heritable Diseases
- CVMD (Cardiovascular & Metabolic Diseases)
- Neurological Diseases



- IP/PCT, Technology, Market & Clinical-Use Analysis
- Value of technologies leveraged via the pre-clinical tests and
- Establish connection within the industry and academia
- Business Partnerships Identification
- Legal Document Review

Business Development Strategy

Technology Marketing

Industrial Partnering

Start Up/ Spin-Off

Product Aspects:

- New Drugs
- Therapeutic Strategies
- Diagnostics
- Bio-Medical Devices



Available Technology for Licensing Out

No.	Topic	Indication
1	A Potential HDAC6 Selective Inhibitor for Alzheimer's Disease	AD
2	Anti-Globo H ADC	Anticancer
3	Development of Novel Anticancer Agent for the Treatment of Malignant Gliomas	Anticancer
4	Hyperactive factor IX variant "FIX-TripleL" for hemophilia B human gene therapy	Gene therapy
5	Klebsiella pneumoniae capsule polysaccharide conjugated vaccines	Vaccine
6	Novel Anticancer Drug, MPT0E028	Anticancer
7	Novel Smo inhibitor for overcoming vismodegib resistance of Hh pathway with anti-cancer activity	Anticancer

Available Technology for Licensing Out

No.	Topic	Indication
8	Reducing Scar Formation	Scar
9	Selective CSF-1R Kinase Inhibitor for Cancer Immunotherapy	Cancer Immunotherapy
10	Selective FLT3 Kinase Inhibitor as Drug for AML	Anticancer
11	Small Molecular PCSK9 Inhibitor for Treating Hypercholesterolemia	Cardiovascular
12	The Novel Iib 3 Antagonist TMV-7 and its Derivative RR Prevent Thrombosis without Increasing Bleeding Risk	Thrombosis
13	Safeguard for Epidural Analgesia	Device
14	Scouting for the Innovative Biotechnologies	



Thank you for your attention !